Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft

New England Journal of Medicine

Volumn 344, Issue 12, 2001, Pages 881-888

  Horwitz, Mitchell E ^a   Barrett, A John ^b   Brown, Margaret R ^c   Carter, Charles S ^c   Childs, Richard ^b   Gallin, John I ^a   Holland, Steven M ^a   Linton, Gilda F ^a   Miller, Judi A ^a   Leitman, Susan F ^c   Read, Elizabeth J ^c   Malech, Harry L ^a   Gress, Ronald E ^d   Schermerhorn, James ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGRAFT; ARTICLE; CHILD; CHIMERA; CHRONIC GRANULOMATOUS DISEASE; CLINICAL ARTICLE; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRANULOMATOUS INFLAMMATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; INFECTION; MALE; PRIORITY JOURNAL; SCORING SYSTEM; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; GRANULOMATOUS DISEASE, CHRONIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTES; MALE; NEUTROPHILS; T-LYMPHOCYTES; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING;

EID: 0035932520     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200103223441203     Document Type: Article

References (46)

1. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease
2. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease
3. Continuous therapy with sulfamethoxazole-trimethoprim in patients with chronic granulomatous disease
4. Chronic granulomatous disease: Report on a national registry of 368 patients
5. Bone marrow transplantation in chronic granulomatous disease
6. Reconstitution of normal neutrophil function in chronic granulomatous disease by bone marrow transplantation
7. Successful bone marrow transplantation in a child with X-linked chronic granulomatous disease
8. Bone marrow transplantation in chronic granulomatous disease
9. Marrow transplantation in chronic granulomatous disease: An update, with 6-year follow-up
10. Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease
11. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B
12. Allogeneic bone marrow transplantation for chronic granulomatous disease
13. Phagocytes: Normal and abnormal neutrophil host defenses
14. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
15. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses
16. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
17. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
18. T-cell depletion of HLA-identical transplants in leukemia
19. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias
20. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for beta-thalassemia major
21. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect
22. Donor lymphocyte infusion at unstable mixed chimerism in an allogeneic BMT recipient for chronic granulomatous disease
23. Flow cytometric analysis of the granulocyte respiratory burst: A comparison study of fluorescent probes
24. Genotype-dependent variability in flow cytometric evaluation of reduced nicotinamide adenine dinucleotide phosphate oxidase function in patients with chronic granulomatous disease
25. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection
26. Pulmonary toxicity associated with fludarabine monophosphate
27. Pulmonary toxicity and acute respiratory failure associated with fludarabine monophosphate
28. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors
29. Bone marrow transplantation in patients with thalassemia
30. Bone marrow transplantation in adult thalassemic patients
31. Bone marrow transplantation for sickle cell disease
32. Haematopoietic stem cell transplantation for sickle cell anaemia: The first 50 patients transplanted in Belgium
33. Treatment of Chediak-Higashi syndrome by allogenic bone marrow transplantation: Report of 10 cases
34. Bone marrow transplantation in 26 patients with Wiskott-Aldrich syndrome from a single center
35. Bone marrow transplantation in major histocompatibility complex class II deficiency: A single-center study of 19 patients
36. Results of allogeneic bone marrow transplantation in patients with leukocyte adhesion deficiency
37. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation
38. Characterization of mixed allogeneic chimeras: Immunocompetence, in vitro reactivity, and genetic specificity of tolerance
39. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10+B10.D2 → B10)
40. Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells
41. Mechanism of protection from graft-vs-host disease in murine mixed allogeneic chimeras. I. Development of a null cell population suppressive of cell-mediated lympholysis responses and derived from the syngeneic bone marrow component
42. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease
43. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: Potential implications for marrow transplantation in humans
44. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen
45. Long-term survival of exthalassemic patients with persistent mixed chimerism after bone marrow transplantation
46. Immune reconstitution following bone marrow transplantation: Comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts